- Home
- CNOB vs DBVT Comparison
CNOB vs DBVT Comparison
Compare CNOB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOB | DBVT |
|---|---|---|
| Founded | 1982 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNOB | DBVT |
|---|---|---|
| Price | $27.87 | $23.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $30.00 | ★ $31.75 |
| AVG Volume (30 Days) | 276.8K | ★ 483.5K |
| Earning Date | 01-29-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $341,316,000.00 | $5,502,000.00 |
| Revenue This Year | $40.81 | $1,768.71 |
| Revenue Next Year | $8.24 | $1,028.88 |
| P/E Ratio | $16.89 | ★ N/A |
| Revenue Growth | ★ 36.38 | N/A |
| 52 Week Low | $20.61 | $3.81 |
| 52 Week High | $29.28 | $26.19 |
Technical Indicators
Market Signals| Indicator | CNOB | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 61.46 |
| Support Level | $26.22 | $21.47 |
| Resistance Level | $28.45 | $24.68 |
| Average True Range (ATR) | 0.93 | 1.55 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 55.07 | 79.28 |
Price Performance
Historical ComparisonAbout CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.